Synergistically targeting synovium STING pathway for rheumatoid arthritis treatment

Rheumatoid arthritis (RA) is a common autoimmune disease leading to pain, disability, and even death. Although studies have revealed that aberrant activation of STING was implicated in various autoimmune dis-eases, the role of STING in RA remains unclear. In the current study, we demonstrated that STING activation was pivotal in RA pathogenesis. As the accumulation of dsDNA, a specific stimulus for STING, is a feature of RA, we developed a spherical polyethyleneimine-coated mesoporous polydopamine nanoparticles loaded with STING antagonist C-176 (PEI-PDA@C-176 NPs) for treating RA. The fabricated NPs with biocompatibility had high DNA adsorption ability and could effectively inhibit the STING pathway and inflammation in macrophages. Intra-articular administration of PEI-PDA@C-176 NPs could effectively reduce joint damage in mice models of dsDNA-induced arthritis and collagen-induced arthritis by inhibiting STING pathway. We concluded that ma-terials with synergistic effects of STING inhibition might be an efficacious strategy to treat RA.

Automated summary

This study demonstrated that STING activation played a crucial role in the pathogenesis of rheumatoid arthritis (RA). Researchers developed PEI-PDA@C-176 NPs nanoparticles as a treatment for RA, targeting the accumulation of dsDNA in RA. These nanoparticles showed good biocompatibility, could effectively inhibit the STING pathway and inflammation in macrophages. Intra-articular administration of PEI-PDA@C-176 NPs effectively reduced joint damage in mouse models of dsDNA-induced arthritis and collagen-induced arthritis by inhibiting the STING pathway.